BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Dec 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemorrhage; Telangiectasis
- Focus Therapeutic Use
- Acronyms BABH Study
- 18 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 28 Jul 2017 New trial record